Second Malignant Neoplasms After Childhood ALL Therapy (PdL-SMN1)

Rigshospitalet

Status: Completed

Conditions: Acute Lymphoblastic Leukemia

Study type: Observational

Funder types: Other; NETWORK

Identifiers

NCT01476462

PdL SMN Study 1

Details and patient eligibility

About

Development of a second neoplasm (SMN) during or after therapy for childhood acute lymphoblastic leukemia (ALL) is a rare event generally associated with a poor prognosis. In this international study we analyze subtypes of SMN in relation to their initial leukemia characteristics and treatment, and their subsequent overall survival.

Full description

To explore epidemiology, potential risk factors and survival rates of second cancers occurring as the first event in childhood acute lymphoblastic leukemia the involved study groups will collect anonymous data on all such cases diagnosed within the last decades to form a common database with predefined variables comprising the clinical, biological, and cytogenetic characteristics (myeloid neoplasias only) as well as outcome. Furthermore, we will register the clinical, biological, and cytogenetic characteristics of the acute lymphoblastic leukemia as well as type of treatment given.

Enrollment: 642 patients

Sex: All

Ages: Under 20 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with childhood acute lymphoblastic leukemia
• Diagnosis of second cancer before December 31st 2007

Exclusion criteria

• Uncertainty if the second cancer has emerged from the same original leukemic clone

Trial design

642 participants in 1 patient group

ALL diagnosed 1980-2007

Description:

Cases of childhood acute lymphoblastic leukemia (ALL) diagnosed between 1980 and 2007 and included in the clinical trials of the participating ALL study groups